RE: covariate on transit compartment model parameters
Hi Jing,
Testing covariates on dispostition of your long acting injectable all depends
on the pharmaceutics. E.g., if you have an intramuscularly injection of a
nano-suspension, you might want to consider a zero order process for the
release of the drug in the systemic circulation and see whether particle size
impacts dissolution rate. In any case, think about the pharmaceutical
plausability first before testing a covariate.
Cheers,
Rob
Quoted reply history
Van: [email protected] [mailto:[email protected]] Namens
Jing Niu
Verzonden: zondag 25 september 2016 14:41
Aan: [email protected]
Onderwerp: [NMusers] covariate on transit compartment model parameters
Dear NMusers,
I am modeling long-acting injectable formulation using transit compartment
model parameterized with mtt (mean transit time) and ntr (number of transit
compartment). As I would like to model multiple formulations using the same
structure model, adding formulation as a categorical covariate on mtt or ntr
separately decreased the OFV significantly (by ~100 units). Considering mtt and
ntr are correlated parameters, should I add formulation on both mtt and ntr, or
adding to either one is sufficient?
Any input is greatly appreciated,
Jing
PS: I am considering the latter one, due to that the simulations with changing
Ktr or ntr generated similar profiles (Fig1 c and d,
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3636497/pdf/psp201314a.pdf).
Het Radboudumc staat geregistreerd bij de Kamer van Koophandel in het
handelsregister onder nummer 41055629.
The Radboud university medical center is listed in the Commercial Register of
the Chamber of Commerce under file number 41055629.